Research & Development
Policy & Regulation
Trends & Finance
Technology Development: Page 3
NIH invests almost $249M in 7 COVID-19 test technologies
In a July 31 press briefing, the NIH discussed seven companies that have received grants for COVID-19 tests through grants from its NIH's Rapid Acceleration of Diagnostics (RADx) initiative, which it says evaluates technology in a similar way as the reality business investment TV show Shark Tank. A range of tests are in development and the award winners include lab-based as well as point-of-care (POC) products. In a statement, the NIH said that the crop of new tests could increase the number of available tests that can be conducted each day by millions, perhaps as early as September. Funding derives from a $1.5 billion appropriation from Congress in April to support new test technologies during the COVID-19 pandemic.
July 30, 2020
LGC acquires antigens and antibodies company NAC
NAC's portfolio includes 60 viral and infectious disease products, including pathogen receptors, virus-like particles and antibodies for immunoassay technologies, and vaccine development and quality control solutions. The global supplier also offers antigens for SARS-CoV-2 to help researchers respond to the COVID-19 pandemic.
July 8, 2020
Sequencing seeks to stay ahead of new COVID-19 surges
Sequencing has been an essential tool for the development of strategies and therapeutics in the fight against COVID-19, and sequencing-based rapid and high-throughput diagnostics for COVID-19 are in development. Sequencing technology suppliers are collaborating with researchers to develop sequencing-based diagnostic tools. For example, several groups are using Illumina's next-generation sequencing (NGS) technology to develop ultrahigh-throughput COVID-19 diagnostic testing.
June 7, 2020
Roche acquires Seattle-based Stratos in bid to achieve sequencing ambitions
Roche is developing a nanopore sequencer and said that the acquisition of Stratos "complements development" of its nanopore technology, which is aimed at providing usable DNA-based information to individuals for making healthcare decisions.
May 21, 2020
Sherlock gets $7.5M to create COVID-19 diagnostics
The nondilutive grant funding will help Sherlock further advance its CRISPR gene-editing technology platform, which it used to create its Sherlock CRISPR SARS-CoV-2 detection kit. The funding will also support the development of the company's Inspectr platform, which powers its COVID-19 diagnostic.
May 20, 2020
MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents
The latest allowances mark MilliporeSigma's 25th and 26th CRISPR patents worldwide and the fourth in the U.S. The company is in discussions to license the foundational technology for therapeutic uses and is seeking collaboration partners for research and development.
May 10, 2020
NIH plan targets new COVID-19 tests, point-of-care options
The NIH's new Rapid Acceleration of Diagnostics (RADx) initiative aims to promote the advance of diagnostic technologies, in collaboration with the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention, and the Biomedical Advanced Research and Development Authority.
April 28, 2020
Rutgers secures EUA for SARS-CoV-2 test
"The impact of this approval is significant," Andrew Brooks, PhD, chief operating officer (COO) and director of technology development at RUCDR, said in a statement released by the university. "It means we no longer have to put [healthcare] professionals at risk for infection by performing nasopharyngeal or oropharyngeal collections."
April 13, 2020
Could mPOC come to the rescue in COVID-19 outbreak?
What IVD technology to use? Lab-based molecular IVD tests are in development, but they can't always be where the need is. Immunoassays take long periods to develop and, generally speaking, may not be sensitive enough for a "must-know" identification task of disease.
March 5, 2020
Illumina unveils megadeal with Roche, new sequencers
The companies said the partnership, which is nonexclusive, will make the most of Illumina's decentralized installed base and Roche's assay development expertise to make next-generation sequencing technology more accessible to cancer patients. Through the deal, Roche gets the rights for the development and distribution of IVD tests on the Illumina NextSeq 550Dx system and future systems. Illumina will manage sales of the systems themselves and consumables.
January 13, 2020
Fusion Genomics secures $1M U.S. to study respiratory infections panel
The Consortium Québécois sur la Découverte du Medicament (CQDM) is a Montreal-based biomedical research consortium that funds new technologies with potential value in facilitating drug discovery and development. The organization noted that since it was founded in 2008, it has raised more than $118 million Canadian ($90 million U.S.) through Canadian government programs and a wide range of pharmaceutical industry partners, including Merck, Pfizer, AstraZeneca, and Eli Lilly.
January 9, 2020
MilliporeSigma licenses CRISPR tech to Promega
Promega will use MilliporeSigma's CRISPR genome-editing technology to create research products and services, including those for drug development.
December 19, 2019
Page 3 of 4